PLK1 and cancer: Previous data suggest that beta-carboline derivatives might inhibit the growth of cancer cells through multiple targets such as DNA topoisomerase [40], [41] and cyclin-dependent kinase [42], [43], but our data indicate that PLK1 is likely the key target based on the following observations.